B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $117 to $155.
Story updates
03:08:06 PM UTC
SquawkNews
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $116 to $136.
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $116 to $136.